Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.1 USD | +9.33% | -1.20% | +6.77% |
Mar. 27 | Acumen Pharmaceuticals Files $200 Million Mixed Shelf | MT |
Mar. 26 | Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+6.77% | 237M | |
+9.16% | 45.97B | |
+54.20% | 43.93B | |
+11.20% | 42.34B | |
-8.59% | 28.27B | |
+16.40% | 27.18B | |
-19.34% | 19.44B | |
+13.95% | 13.83B | |
+31.56% | 12.4B | |
+10.63% | 11.45B |
- Stock
- Equities
- Stock Acumen Pharmaceuticals, Inc. - Nasdaq
- News Acumen Pharmaceuticals, Inc.
- Acumen Pharmaceuticals : Credit Suisse Starts Acumen Pharmaceuticals at Outperform with $26 PT, Notes Sole Product's High-Risk, High-Return Potential